Overview

Rituximab for Pediatric Renal Transplant Rejection

Status:
Completed
Trial end date:
2007-08-01
Target enrollment:
Participant gender:
Summary
Rituximab will be tested for its safety and potential efficacy in treating B cell dense renal allograft rejection episodes in children receiving renal transplants at Stanford University
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Stanford University
Collaborator:
Genentech and Biogen IDEC
Treatments:
Rituximab